Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-001496-11-GB (EUCTR)	15/01/2010	15/03/2010	The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1	The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1	Multiple sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple Sclerosis	Trade Name: Revaxis Product Name: Revaxis	University of Nottingham	NULL	Not Recruiting			Female: yes Male: yes	46	Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4):	United Kingdom
2	EUCTR2009-011523-31-GB (EUCTR)	23/06/2009	16/04/2009	A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC	A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC	The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab. MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1;Classification code 10063400;Term: Secondary progressive multiple sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10046859;Term: Vaccination	Trade Name: Menitorix Trade Name: Pneumovax II Trade Name: REVAXIS	R & D, Cambridge University Hospitals	NULL	Not Recruiting			Female: yes Male: yes	60		United Kingdom